more flexibility and improve their health. Jade Dagher, Head of Sub-Region Canada, Australia & New Zealand spoke about the company’s motive and its new partnership. He said, “At Roche Diabetes Care, our vision is to help people with diabetes think less about their daily diabetes routine so they can focus more on life. This is why we are thrilled to bring this new innovation to Canada to better support the diabetes community. Roche Diabetes Care partnership with Medtronic is a significant advancement for insulin pump users, delivering on our promise to offer integrated patient-centered care solutions that help people living with diabetes”.
The Accu-Chek Guide Link is known for its fast and precise blood glucose readings which surpass accuracy standards. The clinical investigations based on its accuracy led to its approval. This is particularly necessary for diabetic patients who are on insulin therapy, because precise and accurate blood glucose level details are important for making the proper treatment decisions and determining insulin dosage requirements.
The speciality of Roche Diabetes Care is that this new invention will make diabetes care easier for Canadian diabetic patients. The Accu-Chek Guide Link system is now on the market solely to individuals with Type 1 diabetes who are 2 years and above and who use the Medtronic MiniMedTM 770G insulin pump system. To decide if this product is suitable for them, people with diabetes and their caretakers should consult with their healthcare practitioner or diabetes care team.
